Abstract: Disclosed herein is a composition for sustained release of an active that includes a plurality of liposomal beadlets, wherein each of the plurality of liposomal beadlets comprise: a liposomal core comprising phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS) wherein the active is dispersed within the liposomal core; a second core surrounding the liposomal core comprising one or more polypeptide and a polysaccharide; and a polymer beadlet shell surrounding the second core. In certain embodiments, the polymer beadlet shell contains gum arabic; microcrystalline cellulose (MCC); hydroxypropyl methylcellulose (HPMC); glycerol; ?-cyclodextrin; ethyl cellulose; and one or more metal halide salt.

Abstract: A composition for sustained release of an active comprising: a plurality of beadlets, wherein each of the plurality of beadlets comprises: a polymer beadlet shell, wherein the active is dispersed within the polymer beadlet shell, the polymer beadlet shell comprises: gum arabic; microcrystalline cellulose (MCC); hydroxypropyl methylcellulose (HPMC); glycerol; ?-cyclodextrin; ethyl cellulose; and one or more metal halide salts.

Abstract: The invention relates to pharmaceutical compositions comprising dopamine transporter inhibitors and to their use in the prophylaxis or treatment of disease states or conditions mediated by the dopamine transporter.

Abstract: Provided is a Withania somnifera extract composition contains at least one of withaferin A, withanoside IV, withanoside V, withanoside VI, withanolide A, withanolide B, anaferine, anahygrine, 12-deoxywithastromonolide, sitoindoside X, sitoindoside IX, cuscohygrine, isopelletierine, bracteosin A, bracteosin B, or bracteosin C, or a salt or solvate of any one thereof. Related compositions, methods, and processes are also provided.

Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.

Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.

Abstract: This invention relates to a process for preparing a tart cherry extract composition by combining a tart cherry extract with a rosmarinic acid extract. Related compositions and methods are also provided.

Abstract: The invention relates to a process for preparing an elderberry extract composition. The invention also relates to an elderberry extract composition obtainable by the aforementioned process and nutraceutical and pharmaceutical compositions comprising said extract composition.

Abstract: The invention provides a fenugreek extract composition containing at least one of diosgenin, gitogenin, sarsasapogenin, dioscin, protodioscin, pseudoprotodioscin, apigenin or a derivative thereof, luteolin or a derivative thereof, nicotinic acid or a derivative thereof, and kaempferol, or a salt or solvate of any one thereof. Also provided are processes of preparing the extract composition, and nutraceutical and pharmaceutical compositions containing the extract composition.

Abstract: Provided is a Withania somnifera extract composition contains at least one of withaferin A, withanoside IV, withanoside V, withanoside VI, withanolide A, withanolide B, anaferine, anahygrine, 12-deoxywithastromonolide, sitoindoside X, sitoindoside IX, cuscohygrine, isopelletierine, bracteosin A, bracteosin B, or bracteosin C, or a salt or solvate of any one thereof. Related compositions, methods, and processes are also provided.

Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.

Abstract: The invention relates to pharmaceutical compositions comprising dopamine transporter inhibitors and to their use in the prophylaxis or treatment of disease states or conditions mediated by the dopamine transporter.